Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-nodepositive disease and in external-beam radiotherapy series with locally advanced and probably mainly micrometastatic tumors. The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy. At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm (hazards ratio 0.58, 95% confidence interval 0.51-0.66, p ! 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage.
If prostate cancer is organ confined, radical prostatectomy achieves disease-specific 10-year survival rates of about 90% [1] . There are, however, subsets of patients with a markedly less favorable outcome. When disease has spread outside the prostate, survival is compromised. In a multicentric study with 298 stage cT3 patients treated by pelvic lymph node dissection with or without subsequent radical prostatectomy, the prostate cancerspecific 10-year survival rate was only 57% [2] . Radiotherapy alone for locally advanced prostate cancer produced unfavorable results as well [3] . Whereas the longterm outcome after radical prostatectomy is excellent in tumors with a Gleason score of 2-6, the disease-specific 15-year survival is clearly compromised when the Gleason score is 7-10 [4] . In the especially problematic subgroup of patients with Gleason score 8-10 disease, disease-specific 15-year survival after radical prostatectomy is less than 50% [4] . Several clinical trials investigated the effect of adjuvant hormonal therapy to improve these results. Generally, to date, a favorable impact of adjuvant hormonal treatment on survival has only been demonstrated in lymph-node-positive disease and in external- [19] remain the subject of an ongoing debate.
The Bicalutamide Early Prostate Cancer Program
In early breast cancer, adjuvant treatment with the antioestrogen tamoxifen resulted in a significant survival benefit over local therapy only [20] . Since prostate cancer is also a hormone-sensitive tumor, it has been hypothezised that early antiandrogenic therapy may be beneficial in this tumor entity as well [21, 22] . In the 'Bicalutamide Early Prostate Cancer Program' (for clinical stages T1b-4N0-1M0), the nonsteroidal antiandrogen bicalutamide is being evaluated as primary or adjuvant therapy for early prostate cancer. The program consists of three doubleblind, parallel-group trials (one in North America (trial 23, n = 3,292), one in Mexico, South Africa, Australia and Europe (trial 24, n = 3,603), and one in Scandinavia (trial 25, n = 1,218) [22] . In trial 23, all patients underwent radical prostatectomy or radiotherapy prior to study entry. In trials 24 and 25, watchful waiting was possible as a primary management option besides both treatments with cura- Fig. 1 . Freedom from objective clinical progression at 5 years [22] . tive intent [21, 22] . For an exact description of the inclusion and exclusion criteria, see See et al. [22] . With a total of 8,113 patients, this program is the largest currently ongoing study on prostate cancer [23] . The patients were randomized on a 1:1 basis to receive either bicalutamide 150 mg once daily (n = 4,052) or placebo (n = 4,061) [22] . In North America, more than 80% had undergone radical prostatectomy and 20% received radiotherapy prior to randomization, compared to 46 and 18% in the Mexico, South Africa, Australia and Europe trial and 13 and 5% in the Scandinavian trial [22] . In North America, more than 70% of patients entered had a tumor stage of less than T3, compared with approximately 60% in Europe and Scandinavia [22] [23] [24] . The patients received the adjuvant medication for 2 or more years [22] . Time to objective clinical progression (defined as tumor progression confirmed by either biopsy, bone scan, computerized tomography, ultrasound, or magnetic resonance imaging or death of any causes) and survival are the primary end points in the Bicalutamide Early Prostate Cancer Program [21, 22] . Time to treatment failure (withdrawal from treatment), PSA progression (defined as doubling of the PSA value measured immediately prior to the initiation of the application of the study medication) and tolerability are secondary end points [21, 22] . After a median follow-up of 3 years, 38.1% of patients in the bicalutamide group and 31.8% in the placebo group discontinued the treatment. Adverse events were the most common reason for withdrawal from treatment in the bicalutamide group versus disease progression in the placebo group [22] . Gynecomastia and/or breast pain were the most frequent adverse events in the bicalutamide arm with almost 3 of 4 patients being affected [22] . These symptoms improved or resolved after withdrawal of treatment in the majority of cases. Whereas breast pain disappeared in 84% of affected patients within 1 year after cessation of therapy, the resolution rate of gynecomastia depended on the duration of bicalutamide treatment with only 29% resolution in those patients who took the medication for more than 18 months [22] . At the time of the most recently published analysis [22] , 363 patients in the bicalutamide arm and 559 patients in the placebo arm fulfilled the criteria of objective clinical progression ( fig. 1 ). This reduction in the risk of clinical progression by 45% in the bicalutamide arm was highly significant (hazards ratio 0.58, 95% confidence interval 0.51-0.66, p ! 0.0001). This result needs to be qualified by emphasizing that in trial 23, with its much more favorable risk profile, there was no detectable difference concerning objective progression at this time (83 events in the bicalutamide arm and 87 events in the placebo arm). Overall, the reduction in the risk was observed in the whole study population regardless of the primary (curative or noncurative) treatment. Subgroup analyses revealed a hazards ratio of 0.63 (p ! 0.001) for patients who had radical prostatectomy or radiotherapy and of 0.53 (p ! 0.001) for those who did not undergo curative treatment [22] . As expected, the risk reduction was greater in patients with locally advanced disease and in those selected for watchful waiting [22] . Not unexpectedly, considering PSA progression, there was also a highly significant advantage in the bicalutamide arm ( fig. 2) . For a survival analysis, however, there were too few events observed up to the time of analysis, and a longer follow-up is needed to see whether the delayed clinical progression in the bicalutamide arm will translate into a survival advantage which is the most urgent question to be answered. 
Conclusion
Adjuvant treatment for prostate cancer has been shown to provide a survival advantage in patients with histopathologically proven lymph node involvement or with a high risk of microscopic spread. It is, however, still controversial whether a slightly delayed treatment (onset at PSA relapse) may be equally effective. Except for the above-mentioned high-risk patients, randomized trials on adjuvant treatment have so far revealed a delay of progression but no survival advantage in early prostate cancer. The maturation of data of large ongoing trials like the Bicalutamide Early Prostate Cancer Program will increase our knowledge base. However, further studies investigating the appropriate length of adjuvant hormonal therapy are also needed. Efforts are necessary to improve our understanding of factors influencing the survival of men with early prostate cancer.
